Skip to main content

Table 4 Toxicity profiles of AC/SD chemotherapy

From: S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial

  

NCI-CTC AE grade

Toxicities

G1

G2

G3

G4

G5

≥G3 (%)

Hematologic toxicity (by cycle)

      
 

Neutropenia

2/1

1/3

6/6

6/9

0/0

12/15 (6.2/8.7)

 

Febrile neutropenia

0/0

0/0

6/4

0/1

0/0

6/5 (3.1/2.9)

 

Anemia

0/0

0/0

0/1

2/0

0/0

2/1 (1.0/0.6)

Non-hematologic toxicity (by patient)

      
 

Epigastric pain

7/15

3/2

0/6

0/0

0/0

0/6 (0/12.2)

 

Nausea

19/11

8/4

1/2

0/0

0/0

1/2(2.0/4.1)

 

Vomiting

8/9

4/3

1/2

0/0

0/0

1/2 (2.0/4.1)

 

Stomatitis/mucositis

12/14

2/10

0/2

0/0

0/0

0/2 (0/4.1)

 

Infection

0/0

1/1

1/0

0/1

0/1

1/2(2.0/4.1)

 

Increased ALT

0/0

0/2

1/2

0/0

0/0

1/2 (2.0/4.1)

 

Myalgia

6/13

1/7

0/1

0/0

0/0

0/1 (0/2.0)

 

Diarrhea

2/4

2/2

0/1

0/0

0/0

0/1 (0/2.0)

 

Hand-foot syndrome

0/1

0/3

0/1

0/0

0/0

0/1 (0/2.0)

 

Anorexia

18/10

3/9

0/0

0/0

0/0

0/0 (0/0)

 

Constipation

9/8

1/7

0/0

0/0

0/0

0/0 (0/0)

 

Arthralgia

1/2

1/3

0/0

0/0

0/0

0/0 (0/0)

 

Peripheral neuropathy

2/6

0/3

0/0

0/0

0/0

0/0 (0/0)

 

Edema

1/9

0/1

0/0

0/0

0/0

0/0 (0/0)

 

Fatigue

16/0

0/1

0/0

0/0

0/0

0/0 (0/0)

  1. NCI-CTC AE, National Cancer Institute-Common Terminology Criteria for Adverse Events. Total number of cycles delivered was 193/172 cycles for AC/SD.